Abstract
The abstract is not provided being a short comunication / featured article.
Highlights
Antimicrobial resistance (AMR) is one of the leading causes of death globally
Recent estimates reveal that 1.2 million deaths were due to resistant bacterial infections in 2019 and 4.95 million deaths were associated with resistant bacterial infections [1]
This includes nourishing the pipeline, investing in the development of new therapies knowing that research and development (R&D) of safe and effective products takes time, and adopting policy at the government level such as advanced remuneration frameworks to create a viable environment for new products [2]
Summary
Impact Initiatives and Research Coordination Unit, Global Coordination Department, AMR Division, WHO, Geneva, Switzerland. The pandemic has marginalized many public health priorities and programs in countries, resulting in services and programs interruption such as disease surveillance This all together threatens the gains made in recent years against AMR. Today WHO pipeline review is the only global analysis that regularly covers antibacterial agents in development by large pharmaceutical companies as well as by medium and small size enterprises [4]. Findings from this analysis are featured in an annual WHO publication and the data are made public through WHO R&D Observatory [5] as well as the Global AMR R&D Hub. Findings from this analysis are featured in an annual WHO publication and the data are made public through WHO R&D Observatory [5] as well as the Global AMR R&D Hub Overall, this information allows for secondary analyses such as the estimation of the source and number of investments across the different development phases as shown in the Global AMR R&D Hub dashboard [6,7]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
